SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.98+1.1%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: A.J. Mullen6/4/2023 1:07:00 PM
2 Recommendations

Recommended By
Aloner
Lance Bredvold

   of 52153
 
Another reason to get a tumor genotyped. Taking a daily dose of osimertinib halves the post-surgery mortality rate of lung cancer patients with an EGFR mutation. https://www.theguardian.com/science/2023/jun/04/lung-cancer-pill-cuts-risk-of-death-by-half-says-thrilling-study


“It is hard to convey how important this finding is and how long it’s taken to get here,” said Dr Nathan Pennell, an Asco expert who was not involved with the study. “This shows an unequivocal, highly significant improvement in survival.”
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News